Hotchkiss, K. M., Brown, M. C., Owens, E., Threatt, S., Low, J. T., Anand, M., … Khasraw, M. (2025). KS01.6.A INTRATUMORAL IL-12/ANTI-PD-1 ONCOLYTIC HSV1 (MVR-C5252) IS SAFE AND IMMUNOACTIVE IN RECURRENT HIGH-GRADE GLIOMA: PRELIMINARY PHASE 1 RESULTS FROM A MULTICENTER MULTISTAGE CLINICAL TRIAL. In Neuro-Oncology (Vol. 27, pp. iii7–iii7). Oxford University Press (OUP). https://doi.org/10.1093/neuonc/noaf193.020

Hotchkiss, K. M., M. C. Brown, E. Owens, S. Threatt, J. T. Low, M. Anand, M. Goldston, et al. “KS01.6.A INTRATUMORAL IL-12/ANTI-PD-1 ONCOLYTIC HSV1 (MVR-C5252) IS SAFE AND IMMUNOACTIVE IN RECURRENT HIGH-GRADE GLIOMA: PRELIMINARY PHASE 1 RESULTS FROM A MULTICENTER MULTISTAGE CLINICAL TRIAL.” In Neuro-Oncology, 27:iii7–iii7. Oxford University Press (OUP), 2025. https://doi.org/10.1093/neuonc/noaf193.020.

Hotchkiss KM, Brown MC, Owens E, Threatt S, Low JT, Anand M, et al. KS01.6.A INTRATUMORAL IL-12/ANTI-PD-1 ONCOLYTIC HSV1 (MVR-C5252) IS SAFE AND IMMUNOACTIVE IN RECURRENT HIGH-GRADE GLIOMA: PRELIMINARY PHASE 1 RESULTS FROM A MULTICENTER MULTISTAGE CLINICAL TRIAL. In: Neuro-Oncology. Oxford University Press (OUP); 2025. p. iii7–iii7.

Hotchkiss, K. M., et al. “KS01.6.A INTRATUMORAL IL-12/ANTI-PD-1 ONCOLYTIC HSV1 (MVR-C5252) IS SAFE AND IMMUNOACTIVE IN RECURRENT HIGH-GRADE GLIOMA: PRELIMINARY PHASE 1 RESULTS FROM A MULTICENTER MULTISTAGE CLINICAL TRIAL.” Neuro-Oncology, vol. 27, no. Supplement_3, Oxford University Press (OUP), 2025, pp. iii7–iii7. Crossref, doi:10.1093/neuonc/noaf193.020.

Hotchkiss KM, Brown MC, Owens E, Threatt S, Low JT, Anand M, Goldston M, Johnson MO, Bradbury C, Herndon, II JE, Grant GA, Ashley DM, Patel AP, Desjardins A, Khasraw M. KS01.6.A INTRATUMORAL IL-12/ANTI-PD-1 ONCOLYTIC HSV1 (MVR-C5252) IS SAFE AND IMMUNOACTIVE IN RECURRENT HIGH-GRADE GLIOMA: PRELIMINARY PHASE 1 RESULTS FROM A MULTICENTER MULTISTAGE CLINICAL TRIAL. Neuro-Oncology. Oxford University Press (OUP); 2025. p. iii7–iii7.